Aviragen Therapeutics (AVIR) Tops Q1 EPS by 2c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• SWBI beats estimates by 71%, GEO nears 52-week high on policy tailwinds
• FactSet Research Systems (FDS) PT Raised to $253 at Jefferies